a(CHEBI:galanthamine) increases bp(GO:cognition)

View Subject View Object

PubMed:30444369

Only five drugs (Figure 1) have been approved by the U. S. Food and Drug Administration (FDA), four of which are cholinesterase inhibitors (tacrine, 15 donepezil, 16 rivastigmine 17 and galantamine 18 ) and one of which is a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). These pharmacological agents have had limited effect in improving the cognitive function of AD patients and do not slow the progression of the disease. Clinical studies have shown that these agents temporarily stabilize cognitive impairment and help to maintain global function, delaying the need for patient palliative care by only a few month

Related Edges 9

• a(CHEBI:donepezil) increases bp(GO:cognition)
• a(CHEBI:donepezil) decreases act(p(FPLX:Cholinesterase))
• a(CHEBI:galanthamine) decreases act(p(FPLX:Cholinesterase))
• a(CHEBI:memantine) increases bp(GO:cognition)
• a(CHEBI:memantine) decreases act(p(HGNCGENEFAMILY:"Glutamate ionotropic receptor NMDA type subunits"))
• a(CHEBI:rivastigmine) increases bp(GO:cognition)
• a(CHEBI:rivastigmine) decreases act(p(FPLX:Cholinesterase))
• a(CHEBI:tacrine) increases bp(GO:cognition)
• a(CHEBI:tacrine) decreases act(p(FPLX:Cholinesterase))

MeSH

Alzheimer Disease

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.

---